MYC and breast carcinoma: Among these candidates, we focused on the spliceosome inhibitor based on the correlation of spliceosome inhibition and MYC activation as reported in breast cancer [8], lymphomagenesis [22], and glioblastoma stem cells which overexpress MYC [23], but has not as yet been examined in SCLC.